Hutchison China Meditech

July 2013
Fundweb;7/4/2013, p10
Trade Publication
The article focuses on the investment opportunities in Hutchison China MediTech Ltd., the holding company of a pharmaceutical and healthcare group in China.


Related Articles

  • Biotech Review.  // CenterWatch Weekly;10/26/2015, Vol. 19 Issue 42, p11 

    The article offers information related to biotechnology industry including the plan of clinical-stage biopharmaceutical company BeiGene to raised initial public offerings (IPO) on Nasdaq, the filing of IPO by Hutchison China Meditech on Nasdaq, and the cancellation of PO of Acacia Pharma Group.

  • TCM Compound for IBS, Crohn's Moves into Phase III Testing. Ellis, Shannon // BioWorld International;9/18/2013, Vol. 18 Issue 38, p3 

    The article reports on the launching of Phase III trials for a botanical drug known as HMPL-004 in treating inflammatory bowel disease, or ulcerative colitis (UC), via a joint venture between Hutchison China Meditech Ltd. (Chi-Med) of China and Nestle Health Science SA of Lutry, Switzerland. It...

  • Ancient Secrets. Dolan, Kerry A. // Forbes Asia;5/21/2007, Vol. 3 Issue 9, p52 

    The article deals with the plan of Hutchison China Medi-Tech to expand the global appeal of traditional Chinese medicines. MediPharma, subsidy of Hutchison China Medi-Tech, has two drugs derived from Chinese herbs in midstage clinical trials in the U.S., one to improve the potency of radiation...

  • COMPANY SPOTLIGHT - Merck KGaA.  // PharmaWatch: Cancer;Jan2007, Vol. 6 Issue 1, p19 

    The article focuses on the joint venture of German drug maker Merck KGaA and Chinese pharmaceutical company Chi-Med concerning the development of new treatments for cancer in the pharmaceutical industry. The two companies reach into an agreement that Merck will develop new treatments for cancer...

  • COMPANY SPOTLIGHT - Merck KGaA.  // PharmaWatch: Monthly Review;Jan2007, Vol. 6 Issue 1, p41 

    The article reports on a joint venture between Merck KGaA and Chi-Med, both a pharmaceutical company, in developing treatments for cancer with traditional Chinese medicine. The two companies have agreed to develop small molecule anti-cancer drugs using 10,000 natural substances from Chi-Med to...

  • A Chinese. Beacham, Will // ICIS Chemical Business;10/1/2007, Vol. 272 Issue 12, p3 

    The article discusses the use of traditional Chinese medicines by big pharmaceutical companies in search of new chemicals for the drugs. As stated big pharmaceutical companies are collaborating with Asian counterparts supplying Chinese medicines to be used by the western laboratories in drug...

  • Drug & Device Pipeline News.  // CenterWatch Weekly;11/16/2015, Vol. 19 Issue 45, p7 

    A chart is presented depicting the trial status of the drug and device pipeline of several global pharmaceutical companies, including Hutchison China MediTech Ltd., Cymabay Therapeutics Inc. and Kite Pharma Inc.

  • Nestlé and Chi-Med Form Joint Venture to Develop Drugs Based on Traditional Chinese Medicine. Cartwright, Heather // PharmaDeals Review;2012, Vol. 2012 Issue 12, p158 

    The article reports on the 50-50 joint venture (JV) between Hutchison China MediTech Ltd. (Chi-Med) and Nesté Health Science Inc. (NHS) for research, development, and commercialisation of medicines and nutritional products. It says that JV to be named Nutrition Science Partners will focus on...

  • Chrysaor raises funds for Irish exploration.  // Energy Today (Hungary);07/08/2013, p1 

    The article reports that Chrysaor Holdings announced on July 5, 2013 that it has raised 175 million U.S. dollars in equity investment.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics